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ABSTRACT 
 
Objective: To describe 5 cases of Parkinson’s disease lacking any detectable histopathology.   
Background: The diagnosis of Parkinson’s disease is supported histologically by the findings of 
α-synuclein immunopositive Lewy bodies and neurites and severe substantia nigra cell loss. 
Bradykinesia as defined by slowness of initiation of movement and a progressive reduction in 
speed and amplitude on finger tapping is a clinical correlate of pars compacta nigral 
degeneration. There are very few published cases of Parkinson’s disease in which no 
pathological abnormality was found, and some of these cases were in hindsight thought to have 
probably been cases of indeterminate senile tremor or dystonic tremor. 
Methods: Retrospective case notes review of the Queen Square Brain Bank archival collection 
and detailed neuropathological analysis of the selected cases.  
Results: Five cases considered to have Parkinson’s disease by neurologists throughout the 
entirety of their illness that lacked any histopathological findings known to be associated with 
Parkinson’s syndromes were identified out of a total number of 773 brains with a final clinical 
diagnosis of Parkinson’s disease in the Queen Square Brain Bank.  Retrospective case note 
analysis did not suggest dystonic tremor or indeterminate tremor in any of them. There was a 
reduction in tyrosine hydroxylase (TH) density in the striatum in these cases when compared to 
healthy controls, but not in the substantia nigra.  
Conclusions: Striatal dopamine deficiency without nigral cell loss is the most likely explanation 
for the clinical findings; other possible explanations include slowness due to co-morbidities 
misinterpreted as bradykinesia, a tardive syndrome related to undisclosed previous neuroleptic 
exposure, or ‘soft age-related’ parkinsonian signs. These cases emphasise the need to regularly 
review the diagnosis in cases of suspected Parkinson’s disease and highlight the need for 
precision in the neurological examination particularly of elderly patients. These cases may 
represent a distinct entity of diagnostic exclusion and may be considered one explanation for the 
radiological phenomenon of SWEDD (scans without evidence of dopaminergic deficit).   
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INTRODUCTION 
 
The diagnosis of Parkinson’s disease is supported at autopsy by the finding of severe loss of 
neurons in the pars compacta of the substantia nigra associated with α-synuclein immunopositive 
Lewy bodies and neurites. 
1
 There are a few case reports of Parkinson’s disease in which no 
pathological abnormality was found despite detailed histological examination.
2-6
  We now report 
5 patients who were considered to have Parkinson’s disease throughout the entirety of their 
illness,
7-9
 but at post-mortem lacked any histopathological findings associated with any 
recognised neurodegenerative or toxic cause of Parkinsonism.    
 
PATIENTS AND METHODS 
 
Protocols used for brain donation in the QSBB were approved by a London Multi-Centre 
Research Ethics Committee and written consent was obtained from all cases. Tissue is stored at 
the QSBB under a license from the Human Tissue Authority.  
 
Clinical data 
Between 1989 and end of 2014, there were 773 brain donors diagnosed with Parkinson’s disease 
received at the Queen Square Brain Bank (QSBB).  Five cases were identified in which the 
detailed clinical documentation was highly suggestive of Parkinson’s disease and in which the 
pathological diagnosis of Parkinson’s disease, other neurodegenerative parkinsonian syndromes 
and vascular parkinsonism had been excluded at autopsy. All 5 selected cases had   
correspondence between neurologists and general practitioner (GP), full GP record and the 
patient’s full prescription record obtained from the GP practice. Cases with drug-induced 
parkinsonism, whose clinical manifestations were considered to be directly related to 
medications such as dopamine receptor antagonists, were excluded from this study. Two of the 
selected cases (Cases 2 & 3) had a history of short-lived prochlorperazine use for ‘giddiness’.  
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Two cases were pre-registered brain donors and had received standardized prospective annual 
clinical assessments (Cases 4 & 5), one attended a regional neurological centre (Case 3) and 
three (Cases 1, 2 & 5) were followed up regularly throughout their illness in movement disorder 
clinics.  
Complete clinical notes were obtained on all patients and retrospective case notes review was 
undertaken by three QSBB associated clinicians (HL, SK, HY) who formulated independent 
clinical summaries.  Consensus opinion on each case was reached by two other clinicians (AJL, 
LSM).  None of the patients had dopamine transporter scans and no video recordings of the 
patients were available.    
 
Neuropathological methods 
Immediately after post-mortem, the brains were divided in the mid-sagittal plane. One half, 
chosen randomly, was sliced and tissue blocks were frozen and stored, while the other half was 
immersed and fixed in 10% neutral formalin for three weeks before neuropathological 
examination. Tissue blocks were taken using standard QSBB protocols. 8-µm thick histological 
sections were stained with haematoxylin and eosin method. Immunohistochemistry with 
antibodies to α-synuclein (frontal, parietal and temporal cortices, hippocampus, amygdala, 
midbrain, pons), Aβ (frontal, parietal and temporal cortices, hippocampus, caudate, putamen, 
globus pallidus, midbrain, pons, cerebellum), phospho-tau (AT8; frontal, parietal and temporal 
cortices, hippocampus, amygdala, caudate, putamen, globus pallidus, subthalamic nuclei, 
midbrain, pons, cerebellum), p62 (frontal cortex, hippocampus, caudate, putamen, globus 
pallidus, cerebellum) and TAR DNA-binding protein 43 (TDP-43; hippocampus, amygdala) was 
carried out in selected brain regions using standard avidin-biotin method. Immunohistochemistry 
with tyrosine hydroxylase antibody (TH, caudate, putamen, midbrain) antibody was performed in 
5 age- and disease duration-matched Parkinson’s disease cases and 5 age-matched healthy 
controls.  
Systematic histological analysis of neuronal loss in the substantia nigra and examination of the 
immunohistochemistry sections in search of inclusions known to be associated with clinical 
parkinsonism were performed by a neuropathologist (TR). Neuronal loss in the substantia nigra 
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was determined using a four-tier semi-quantitative grading (0=absent, 1=mild, 2=moderate, 3= 
severe). Additional pathologies including cerebrovascular disease and cerebral amyloid 
angiopathy and Alzheimer’s disease pathologic change were carefully assessed. 
10
  
 
Image analysis of TH-immunoreactivity  
 
Using coded slides, quantitative assessment of TH-immunoreactivity was performed in 4 
subregions of the striatum (dorsal putamen, ventral putamen, dorsal caudate and ventral caudate) 
and 4 subregions of the substantia nigra pars compacta (dorsal lateral, ventral lateral, dorsal 
medial and ventral medial). The images of the striatum and substantia nigra pars compacta using 
x20 objective were captured by a high resolution digital scanner and processed with image 
analysis software (Definiens TissueMap image analysis software Version 3.0, Definiens AG, 
Germany). Threshold was adjusted to capture the two-dimensional area of all TH-
immunoreactivity and the same threshold setting was used for all the subregions in all cases 
included in the analysis. ‘Areal fraction’, defined by a ratio of the TH-immunoreactive pixels to 
the total number of pixels of the whole field was computed by the image analysis software and 
was expressed as percentage (areal fraction x 100%). 
11
  
 
Statistical analysis 
 
The Mann-Whitney U-test was used to compare areal fraction percentage between cases in the 
present series and control groups. In this exploratory study, statistical significance was set at p < 
0.05 and results were not adjusted for multiple comparisons. Chi square/Fisher’s exatct test, the 
Student’s t-test or oneway ANOVA was used to compare semi-quantitative grading or 
demographic data using p value of 0.05. The SPSS 22.0 program (IBM Corporation, New York, 
USA) was used for statistical analysis.  
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RESULTS 
 
All five patients had presenting features and a clinical course highly suggestive of Parkinson’s 
disease. Four of them presented with a levodopa responsive asymmetrical rest tremor. The mean 
age at onset was 70.8 years (range: 55-83) and the mean disease duration was 11 years (range: 4-
18). None of the cases had a positive family history of movement disorder. Other clinical 
demographics are summarized in Table 1. Only 1 case (Case 5) had neuroimaging study, CT of 
the head was performed two years before death following a fall and no structural abnormalities 
were reported.  
 
Case reports 
 
Case 1 
This 86-year-old man presented to his GP in 2006 with a 3-year history of gradually worsening 
right hand tremor and a 6 month history of poor balance and ‘giddiness’ on standing up.  A pill 
rolling tremor of the right hand, bilateral cogwheel rigidity and shuffling gait were observed by 
his GP and a diagnosis of Parkinson’s disease was made.  He was subsequently referred to a 
specialist movement disorder clinic and one year after his first symptoms he was noted to have 
had a sustained marked improvement following treatment with levodopa/carbidopa 62.5mg four 
times daily. A festinant gait, reduced arm-swing and bilateral, asymmetrical cogwheel rigidity 
were now noted.  Ropinirole 1mg three times daily was added and a further symptomatic 
improvement in stiffness and mobility occurred but he developed light-headedness due to 
orthostatic hypotension. At this stage he was recruited to a Parkinson’s disease trial.  He 
remained under regular review with slow but progressive motor deterioration until he died aged 
88 from a pulmonary embolism secondary to lung carcinoma, 5 years after his clinical diagnosis 
of Parkinson’s disease. 
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Case 2 
In 2001, a 78-year-old woman was diagnosed with Parkinson’s disease by a consultant 
neurologist at a movement disorder clinic after presenting with a 10-month history of progressive 
worsening of general slowness and a tremor at rest.  On examination, a marked bilateral rest 
tremor of the hands was observed in addition to a head tremor, bilateral bradykinesia, cogwheel 
rigidity, reduced blink rate and impaired postural reflexes.  She had difficulty rising from a chair 
and her gait was of reduced stride length, with episodes of freezing.  Levodopa/carbidopa 125mg 
three times daily was started but at review 2 months later, she was thought to have deteriorated.  
She started to have occasional falls backwards.  The medication records from the general 
practitioner showed she was prescribed prochlorperazine 5mg for a few weeks for vertigo during 
the period of reported rapid deterioration.  The prochlorperazine prescription was not repeated 
and her levodopa dose was gradually increased to 750mg daily and over the following 2 years 
some of the doctors who saw her considered her to have improved, while others commented that 
her parkinsonism had stabilized.  She reported subjective worsening of her symptoms at the end 
of each levodopa dose, but she did not experience clear benefit from individual doses and on one 
occasion she inadvertently decreased her dose and did not notice any worsening.  She died 4 
years after the diagnosis of Parkinson’s disease from bronchopneumonia, aged 81.  
 
Case 3 
In 1992, at age 59, this woman with a previous history of several non-specific symptoms was 
diagnosed with ‘parkinsonism’ by her GP after finally presenting with limb stiffness and a right 
sided tremor.  She was taking prochlorperazine, which was withdrawn and she was subsequently 
seen by a consultant neurologist who documented ‘parkinsonism with a right-sided emphasis’ 
and started on levodopa/carbidopa 62.5mg twice daily. She complained of slowing of her 
handwriting but a letter written by her to the GP did not reveal micrographia (Figure 1).  After 
several years of follow up she was considered to have ‘benign tremulous parkinsonism’. Her 
levodopa dose was gradually increased, reaching a peak of 1250mg daily when, she reported 
unilateral involuntary facial movements that were thought to be levodopa-induced dyskinesias, 
but were later diagnosed as hemifacial spasm.  A dispersible formulation of 
levodopa/benserazide was prescribed to treat nocturnal rigidity.  Progressive deterioration in her 
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mobility due to a combination of Parkinson’s disease and lumbar degenerative disease led her to 
be wheelchair dependent 8 years after her diagnosis of Parkinson’s disease.  In the last year of 
her life, there were reports in her notes of involuntary wild ‘twitching’ movements following the 
intake of levodopa.  She continued to be treated for Parkinson’s disease for 12 years until she 
died from bronchopneumonia and heart failure aged 71.  
 
Case 4 
This man was diagnosed with Parkinson’s disease in 1976 by his GP at the age of 55 after 
presenting with limb stiffness. Examination two years after the initial diagnosis revealed a 
‘mask-like face’, a positive glabellar tap response and rigidity in the limbs with a right-sided 
predominance. He was started on levodopa/carbidopa 110mg twice daily two years after 
diagnosis. At his first assessment by a consultant neurologist, the patient reported his initial 
response to levodopa to be excellent.  Seven consecutive annual QSBB prospective assessments 
all reported mild to moderate, usually symmetrical, bradykinesia and rigidity with no 
deterioration in his Hoehn and Yahr stage from the baseline level of 2.  His levodopa dose was 
gradually titrated up to 750mg per day but he did not experience motor fluctuations or 
dyskinesias.  He died from bronchopneumonia complicating myeloma after 18 years of disease. 
 
Case 5 
This woman was diagnosed with Parkinson’s disease by her GP in 1987 at the age of 84 after 
presenting with a 4-year history of progressive bilateral rest tremor of the hands. An initial 
QSBB assessment form filled in by an affiliated neurologist in 1993 reported a Hoehn and Yahr 
stage of 2. Examination by a neurologist revealed mild bilateral limb rigidity, severe tremor in 
the hands and legs. She was commenced on levodopa/carbidopa 125mg which was gradually 
titrated up to four times daily. She reported a good response to levodopa therapy. Three years 
later, she noted mild choreiform movements of her head and neck on reaching the maximum 
levodopa dose and transient worsening of her motor symptoms coincided with the end of each 
dose of levodopa. Between 1990 and 1997, she was regularly followed up in a Parkinson’s 
disease clinic and progressive deterioration in the tremor of her head and hands, mobility and 
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gait freezing was documented. At the age of 93, she developed marked postural instability, 
freezing of gait and falls. She could only walk a few steps using a walking frame. She 
complained of drooling of saliva and difficulty in swallowing. She died after 15 years of disease 
and the cause of death was recorded as ‘end-stage Parkinson’s disease’.  
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Table 1: Clinical demographics of the five cases included in this case series. 
 
 Case 1 Case 2 Case 3 Case 4 Case 5 
Gender Male Female Female Male Female 
Age at onset 83 77 59 55 80 
Age at death 
(Disease 
duration) 
88 (5) 81 (4) 72 (13) 73 (18) 95 (15) 
Initial 
presentation 
Rest tremor 
(Right hand) 
Rest tremor (Left 
hand), 
parkinsonian gait 
Rest tremor (Right 
hand) 
Generalized 
slowing 
Bilateral hand 
tremor 
Other 
symptoms and 
signs 
Asymmetric 
rest hand 
tremor, rigidity 
& reduced 
armswing, 
festinant gait, 
falls, postural 
hypotension, 
abnormal 
glabellar 
response 
Asymmetric rest 
hand tremor, head 
and leg tremor, 
bradykinesia, 
general slowness, 
rigidity, gait 
freezing, falls, 
hypomima 
Asymmetric rest 
hand tremor, 
rigidity, slow 
handwriting, 
general slowness, 
rigidity, postural 
instability 
(wheelchair use at 
age 69)  
Asymmetric 
bradykinesia 
and rigidity, 
occasional rest 
hand tremor, 
hypomimia, 
abnormal 
glabellar 
response, 
hypomimia 
Head and leg 
tremor, 
rigidity, 
postural 
instability & 
recurrent falls 
(age 93), 
dysphagia 
(age 94)   
Predominant 
tremor?  
Yes Yes Yes No Yes 
Initial 
levodopa 
response 
Excellent 
(improved all 
motor 
symptoms) 
Mild Moderate Good Good 
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Sustained 
levodopa 
response?  
Yes Yes Yes Yes Yes 
Max levodopa 
equivalent 
dose 
320mg/day 1200mg/day 1250mg/day 1200mg/day 400mg/day 
Motor 
fluctuation 
No Mild wearing off Generalised 
twitching 
movements at peak 
dose, wearing off  
No Mild 
choreiform 
movements of 
head at peak 
dose, wearing 
off  
Visual 
hallucinations 
No No No No No 
Memory 
impairment 
No No No Mild cognitive 
impairment 
(MMSE 
scores: 23-
30/30) 
No 
Disease 
progression 
Slow 
progression 
only before 
levodopa with 
subsequent 
plateau 
Initial rapid 
progression with 
subsequent plateau 
Gradual 
deterioration 
No 
progression  
Gradual 
deterioration  
Co-
morbidities   
Ischaemic 
heart disease 
Depression, 
COPD  
Anxiety, 
depression,  
hemifacial spasm, 
osteoarthritis, 
osteoporosis, 
cervical 
spondylosis, 
Anxiety, 
migraine, 
ischaemic 
heart disease 
Ischaemic 
heart disease, 
pulmonary 
tuberculosis 
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chronic back pain, 
Sjogren’s 
syndrome, asthma 
Features 
against 
Parkinson’s 
disease 
No record of 
bradykinesia 
Head tremor, mild 
levodopa 
response, transient 
use of 
prochlorperazine 
(coincided with 
worsening of 
parkinsonism) 
No record of 
bradykinesia, 
intermittent use of 
prochlorperazine 
(stopped when first 
diagnosed with 
Parkinson’s 
disease) 
Mild motor 
symptoms, 
lack of 
progression 
Head tremor, 
lack 
asymmetry or 
record of 
bradykinesia 
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Pathological Findings  
None of the cases was deemed to have a pathological explanation for parkinsonism. No cases 
met the criteria for the pathological diagnosis of Parkinson’s disease, vascular parkinsonism or 
other neurodegenerative parkinsonian syndromes. Staining for α-synuclein was negative in the 
medulla and substantia nigra in all cases confirming the absence of Lewy body pathology. 
Macroscopic examination was unremarkable with normal pigmentation of the substantia nigra 
and absence of cortical atrophy or ventricular dilatation. Mild nigral cell loss compatible with 
aging was found in three cases (1, 3 & 4) with evidence of negligible free pigment (1 & 3). The 
substantia nigra in the remaining two cases was normal (2 & 5; Figure 2). The locus coeruleus 
was normal in four cases (cases 1, 2, 4 & 5) but was unavailable for examination in case 3. The 
subthalamic nucleus, corpus striatum and thalamus were normal in all five cases with no cell loss 
or pathological inclusions. 
No cases exhibited extra-nigral pathology deemed sufficient to cause clinical parkinsonism.  In 
two cases (cases 1 & 3) there was mild mineralisation of blood vessels in the globus pallidus.  
Case 1 also had mild hyaline arteriolar thickening in the deep white matter and mild cerebral 
amyloid angiopathy, with the extent of vascular change being slightly more than expected for the 
patient’s age.  Mild perivascular accentuation associated with a mild degree of gliosis in the 
striatum was observed in 4 cases (1-4).  These findings are common in older individuals and 
were not of the degree observed previously in vascular parkinsonism cases 
12 13
 and judged not 
severe enough to account for parkinsonism.  Mild age-related Alzheimer’s type tau pathology 
was identified in all cases at Braak and Braak stage II or below. 
10
 Immunohistochemistry with 
TDP-43 was negative in all cases. 
Neuropathological examination including immunohistochemistry excluded any structural causes 
and confirmed the absence of any distinctive histological hallmarks for any of the 
neurodegenerative entities listed in Table 2. Genetic analysis performed in all five cases using 
DNA obtained from frozen brain tissue excluded mutation of the Huntington’s disease gene 
(repeat size: 18-26). 
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Image analysis of TH-immunoreactivity 
TH synthesises dopamine from tyrosine and TH immunohistochemistry is used as a marker of 
catecholaminergic fibres including dopaminergic neurons.  
Quantitative assessment of the density of TH-immunoreactivity was performed in these 5 cases 
(mean age of death: 81.8 years, mean disease duration: 11 years), 5 age- and disease duration-
matched Parkinson’s disease controls (mean age of death: 79.8 years, p = 0.32; mean disease 
duration: 14.2 years, p = 0.76) and 5 age-matched healthy controls (mean age of death: 77.0 
years, p = 0.16). 
14
  
In all subregions of the substantia nigra pars compacta, there was reduction in the TH density in 
Parkinson’s disease when compared with the present cohort (dorsolateral: p = 0.009, 
ventrolateral: p = 0.009, dorsomedial: p = 0.028, ventromedial: p = 0.009) and the healthy 
controls (dorsolateral: p = 0.014, ventrolateral: p = 0.014, dorsomedial: p = 0.014, ventromedial: 
p = 0.027). The TH density was the same between the present cohort and healthy controls 
(dorsolateral: p = 0.806, ventrolateral: p = 0.462, dorsomedial: p = 0.624, ventromedial: p = 
0.806; Figure 3).   
In the striatum, the TH density in the dorsal putamen (p = 0.034), ventral putamen (borderline 
significance; p = 0.077) and ventral caudate (p = 0.034) of the present cohort was less than that 
of the healthy controls, but not in the dorsal caudate (p = 0.289). The TH density in the present 
cohort was numerically greater than Parkinson’s disease controls but it did not reach statistical 
significance (dorsal putamen: p = 0.149, ventral putamen: p = 0.149, dorsal caudate: 0.248, 
ventral caudate: 0.386; Figure 4 & 5). 
 
 
 
 
Page 15 of 37
https://mc.manuscriptcentral.com/jnnp
Journal of Neurology, Neurosurgery, and Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
 
Table 2: Potential explanations for Parkinson’s disease mimics without nigral atrophy and Lewy 
body pathology. 
Neurodegenerative causes: 
Huntington’s disease 
Fragile X tremor ataxia syndrome (FXTAS) 
Chronic traumatic encephalopathy 
C9orf72 expansion 
Spinocerebellar ataxia (SCAs) 
Non-neurodegenerative causes: 
Mild extrapyramidal signs of the elderly 
Indeterminate or senile tremor 
Dystonic tremor 
Tardive parkinsonism 
Vascular parkinsonism 
Psychomotor retardation due to depression 
Rheumatological or orthopaedic conditions (e.g. arthritis, spondylosis) 
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DISCUSSION 
 
It came as a surprise that with the use of dopamine transporter SPECT scans, up to 15% of 
patients in trials for early Parkinson’s disease had no evidence of presynaptic nigrostriatal 
dopamine denervation. 
15-17
 The radiological acronym SWEDD (standing for scans without 
evidence of dopaminergic deficit) was used to describe these patients, and there is ongoing 
debate regarding their true diagnosis. Repeat dopamine transporter scans often remain normal 
with only 8-13% converted to have an abnormal scan up to five years later.
18-20
 Almost half of 
the SWEDD patients (40/90) in the PRECEPT Parkinson’s disease clinical trial (N=799) had 
their diagnosis changed to a condition not associated with dopamine denervation at 22-month 
follow-up by study investigators blinded to the dopaminergic scan status with the most common 
revised diagnosis being tremor, followed by ‘no neurological diagnosis’ and vascular 
parkinsonism,
19
  highlighting the diagnostic difficulties in the early disease stage, and even in 
Parkinson’s disease patients with SPECT-confirmed dopaminergic deficits (N=707), 5 cases had 
been re-evaluated as having a tremor syndrome not associated with dopamine denervation and 13 
had their diagnosis revised to vascular parkinsonism.
19
 SWEDD patients generally had milder 
motor disability as measured by UPDRS,
19
 their clinical symptoms tended to be stable with no 
deterioration after withdrawal of levodopa therapy
19
 and they present with less non-motor 
features,
21 22
 all of which might be useful clinical pointers. Most neurologists now consider that 
these patients do not have Parkinson’s disease. 
18 19
  Some of the tremulous patients with 
SWEDD can present with dystonic features
23
 and abnormal cortical plasticity
21
 suggesting that 
dystonic tremor could be the underlying diagnosis. Patients with dystonic and indeterminate 
senile tremor may have reduced armswing, small stride length, asymmetric jerky rest and 
postural tremor, hypomimia, increased limb tone and slow repetitive finger movements and it has 
been claimed that 3% of dystonic tremor are misdiagnosed with Parkinson’s disease.
23-25
 
Nevertheless, many SWEDD patients do not fall into this phenotype and pathological findings in 
SWEDD have not been published. 
Slowness of initiation of movement or reduced amplitude of movements without motor 
decrement may be seen in dystonia or pyramidal slowness,
24 26
 but bradykinesia with motor 
decrement and fatiguing has been considered a clinical correlate of nigral deficiency. The QSBB 
Page 17 of 37
https://mc.manuscriptcentral.com/jnnp
Journal of Neurology, Neurosurgery, and Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
 
diagnostic criteria stipulate that the presence of bradykinesia is obligatory for the diagnosis of 
parkinsonism.
7
 On reexamination, some SWEDD subjects from clinical series exhibited 
slowness or reduction of amplitude, but no true motor decrement
21 23
 highlighting the  
importance of repetitive finger tapping tests performed for 20 -30 seconds in the clinical 
differentiation between  Parkinson’s disease and SWEDD patients.
27
  Nevertheless, a recent 
blinded video study showed that even experienced movement disorder specialists may have 
difficulty distinguishing slowness in SWEDD from bradykinesia in Parkinson’s disease.
28
 Our 
findings support this area of clinical uncertainty in that three of our patients were considered to 
have either bradykinesia (Cases 2, 4) or general slowness (Case 3).  We cannot exclude the 
possibility that slowness due to aging or co-morbidities (depression, arthritis, spondylosis) was 
misinterpreted as criteria-defined bradykinesia in some of these cases.  
One could argue that the slow rate of deterioration should have cast doubt on the clinical 
diagnosis of Parkinson’s disease.  Case 4 had Parkinson’s disease for 18 years with little 
progression.  Cases 3 and 5 had a gradual deterioration over 13 and 15 years.  Case 2 initially 
had a rapidly progressive course, during which she was also receiving prochlorperazine, 
followed by a “stabilization of symptoms” after prochlorperazine withdrawal.  In contrast, Case 
1 exhibited a very typical course for Parkinson’s disease, with a rest tremor at onset that 
progressed to a shuffling gait in the pre-treatment phase, but no further progression reported after 
commencing dopaminergic medication.  Although Parkinson’s disease is always progressive, 
heterogeneity exists in the rate of deterioration with some patients following a relatively mild 
course, remaining in stage 1 or 2 Hoehn and Yahr for up to 10 years. 
29
 Clinically, 4 of 5 of these 
cases had a tremor-predominant clinical picture and can mimic benign tremulous parkinsonism, a 
pathologically proven subtype of Parkinson’s disease which is associated with a relatively slow 
rate of clinical progression at least in the early or mid-disease stage.
30
 Our cases raise the 
possibility that a small proportion of those slowly progressive cases might in fact not have 
underlying nigral degeneration.  
All the patients had some benefit from levodopa; Case 1 had adequate documentation of 
sustained levodopa responsiveness, while cases 2, 3 and 5 exhibited wearing off effects 
described in the notes.  Occasional episodes of generalised twitching movements were reported 
at peak dose in case 3 in the last year of life and mild choreiform head movements were noted at 
peak dose of levodopa therapy in case 5. Marked initial and sustained levodopa responsiveness 
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are features supportive of the diagnosis of Parkinson’s disease, with 75% of pathologically 
confirmed Parkinson’s disease exhibiting a good or excellent initial levodopa response.
7
  The 
presence of severe levodopa-induced chorea has a high positive predictive value for the 
diagnosis of Parkinson’s disease and is included as a supportive feature in Parkinson’s disease 
diagnostic criteria.
7 31 32
 However, in pathologically proven Parkinson’s disease a poor or 
moderate levodopa response was noted in 17% cases, and no dyskinesias or motor fluctuations 
were reported in 34%.
7
  Furthermore, dyskinesias are less common in poorly levodopa 
responsive patients or in the absence of motor fluctuations, with one recent clinic-pathological 
study reporting dyskinesia in only 14% of non-fluctuators.
33
 The levodopa responses reported in 
our cases are clearly comparable to those seen in pathologically confirmed Parkinson’s disease, 
highlighting further potential for diagnostic error.  
Although not the primary emphasis of this paper, these cases provide a unique opportunity to 
observe clinical and pathological effects of long-term levodopa on healthy human substantia 
nigra.  All patients received levodopa for at least 21 months (up to 216 months) in doses ranging 
from 200 to 1250 mg daily.  Although three patients reported side effects, the lack of 
pathological change in our cases provides further reassurance that levodopa is not toxic to human 
substantia nigra.
4
  
The severe loss of dopamine-containing neurons from the pars compacta of the substantia nigra 
is the pathological hallmark of Parkinson’s disease and the prerequisite for the development of 
motor symptoms. This loss of dopaminergic neurons is accompanied by Lewy bodies of which 
the main component is α-synuclein 
1
. Unlike neurofibrillary tangles in tauopathies, a constant 
proportion of nigral neurons of 3-4% contains Lewy bodies irrespective of the disease duration, 
supporting the notion that Lewy bodies are eliminated when the neurons that bear them die and 
that Lewy bodies are at the same time being constantly produced. 
34
 Based on current 
clinicopathological concepts of disease, the patients in the present series cannot be said to have 
had Parkinson’s disease.  In most of the previously reported cases of Parkinson’s disease without 
pathological explanation, the phenotype was predominantly tremulous, there was absent or 
debatable bradykinesia and rigidity
3-5
 and there was no significant response to levodopa with 
successful levodopa withdrawal in one case.
5
  Furthermore, in retrospect, there were sufficient 
features to support a revised clinical diagnosis of essential tremor, atypical tremor or dystonic 
tremor retrospectively.
2 4 5
 In contrast, the cases in this series had cardinal motor features of 
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Parkinson’s disease and had been followed by neurologists for prolonged periods. The clinical 
presentations in cases 1, 3 and 4 would be incompatible with essential tremor, atypical tremor or 
dystonic tremor. Although in cases 2 and 5, a head tremor was observed, the impaired postural 
response and gait freezing would be unusual for indeterminate or senile tremor, and head tremor 
has been reported in Parkinson’s disease. 
35
  
TH density in the striatum in the cases in this series is reduced to a similar degree as that of 
Lewy body Parkinson’s disease, but such reduction is not identified in the substantia nigra. In the 
absence of neuronal loss in the substantia nigra and striatum as shown by semi-quantitative 
assessment, the findings of TH-immunohistochemistry suggest a biochemical deficiency of 
dopamine. In dopa-responsive dystonia, there is selective nigrostriatal dopamine deficiency 
caused by genetic defects in the dopamine synthetic pathway without nigral cell loss and it is not 
considered a neurodegenerative disorder, but a biochemical disorder in which symptoms can be 
reversed by replacement of the depleted neurochemicals. 
36
 The reduction in TH density in cases 
in this series could only be identified by sensitive stereological image analysis rather than 
standard histopathological method, but we cannot exclude the possibility of mild loss of 
dopamine-containing terminals in these cases. Striatal dopamine deficiency is the most likely 
explanation for the clinical findings of parkinsonism and positive levodopa response in these 
cases. Its underlying cause however will warrant further study which is beyond the scope of this 
series. Other credible arguments can be proposed as to why these patients had parkinsonism and 
in some cases responded to levodopa. Undisclosed continued neuroleptic use or a tardive 
phenomenon (Cases 2 &3) following neuroleptic exposure in two of the cases could also be 
speculated. 
37
 All the patients were elderly and it may be that they had soft extrapyramidal signs 
related to aging that were confused with Parkinson’s disease. 
38 39
  
Dopamine transporter locates in the presynaptic membrane on the terminals of dopaminergic 
projections from the substantia nigra to the striatum and it provides a marker for dopamine 
terminal innervation. 
40
 Dopamine transporter SPECT is normal in dopa-responsive dystonia.
41 42
 
We speculate that the result of the scan in these 5 cases would also have been reported as normal 
on visual assessment but semi-quantitative assessment might have revealed subtle reduction in 
tracer uptake in the striatum. We conclude that these 5 cases probably represent a subgroup of 
SWEDD cases and it may be reasonable to assume that SWEDD is an entity of diagnostic 
exclusion with several distinct causes.
19
 Our cases serve to highlight the need for ongoing 
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clinico-pathological research and highlight the need to review the clinical diagnosis including the 
judicious use of dopamine transporter scans, even in patients with longstanding disease if 
atypical features exist.   
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FIGURE LEGENDS 
 
Figure 1: 
An example of the handwriting of case 2. A letter written by the patient at age 68 to her GP eight 
years after the onset of her initial symptoms of asymmetric rest tremor of the hands. There is no 
evidence of micrographia but patient complained of slowness. 
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Figure 2: 
Substantia nigra of a case example of Parkinson’s disease and case 2. In the Parkinson’s disease 
case, severe degree of cell loss of pigmented neurons and gliosis (A-1, x4 objective) and Lewy 
bodies and Lewy neurites containing α-synuclein (α-syn, A-2, x10 objective) in the substantia 
nigra are evident. In case 2,  the substantia nigra is well preserved without evidence of neuronal 
loss or gliosis (B-1, x4 objective) and no Lewy bodies or Lewy neurites are identified using α-
synuclein immunohistochemistry (B-2, x4 objective). 
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Figure 3: Substantia nigra of a healthy control, case 1 and a Parkinson’s disease (PD) control 
(x4 objective). Severe neuronal loss, gliosis and markedly reduced TH density can be observed 
in the PD case. TH density in the substantia nigra is preserved in Case 1 and healthy control. 
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Figure 4: Tyrosine hydroxylase (TH)-immunohistochemistry in the dorsal putamen (x4 
objective) of a healthy control, case 1 and a Parkinson’s disease (PD) control. TH density is 
markedly reduced in the PD control and mildly reduced in case 1 when compared with healthy 
control.  
 
 
 
Page 25 of 37
https://mc.manuscriptcentral.com/jnnp
Journal of Neurology, Neurosurgery, and Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
 
Figure 5: Tyrosine hydroxylase (TH)-immunohistochemistry in 4 subregions of the striatum 
(x20 objective) of a healthy control, case 1 and a Parkinson’s disease (PD) control. When 
compared with healthy controls, TH density is reduced in the striatum in PD controls and, to a 
lesser extent, in the cases in this series.  
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An example of the handwriting of case 2. A letter written by the patient at age 68 to her GP eight years after 
the onset of her initial symptoms of asymmetric rest tremor of the hands. There is no evidence of 
micrographia but patient complained of slowness.  
254x190mm (300 x 300 DPI)  
 
 
Page 33 of 37
https://mc.manuscriptcentral.com/jnnp
Journal of Neurology, Neurosurgery, and Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
  
 
 
Substantia nigra of a case example of Parkinson’s disease and case 2. In the Parkinson’s disease case, 
severe degree of cell loss of pigmented neurons and gliosis (A-1, x4 objective) and Lewy bodies and Lewy 
neurites containing α-synuclein (α-syn, A-2, x10 objective) in the substantia nigra are evident. In case 
2,  the substantia nigra is well preserved without evidence of neuronal loss or gliosis (B-1, x4 objective) and 
no Lewy bodies or Lewy neurites are identified using α-synuclein immunohistochemistry (B-2, x4 objective). 
254x190mm (300 x 300 DPI)  
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Substantia nigra of a healthy control case, case 1 and a Parkinson’s disease (PD) control (x4 objective). 
Severe nigral cell loss and gliosis and markedly reduced TH-immunoreactivity can be observed in the PD 
case. The substantia nigra and its dopamine-containing terminal (shown by TH density) are preserved in 
Case 1 and healthy control.  
375x191mm (300 x 300 DPI)  
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Tyrosine hydroxylase (TH)-immunohistochemistry in the dorsal putamen (x4 objective) of a healthy control, 
case 1 and a Parkinson’s disease (PD) control. TH density is markedly reduced in the PD control and mildly 
reduced in case 1 when compared with healthy control.  
336x96mm (300 x 300 DPI)  
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Tyrosine hydroxylase (TH)-immunohistochemistry in 4 subregions of the striatum (x20 objective) of a 
healthy control, case 1 and a Parkinson’s disease (PD) control. When compared with healthy controls, TH 
density is reduced in the striatum in PD controls and, to a lesser extent, in the cases in this series.  
367x367mm (300 x 300 DPI)  
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